Robins bankruptcy violation
Executive Summary
Richmond Federal Court ruled that firm improperly awarded over $1.5 mil. in bonuses to 16 retired execs after filing for bankruptcy last August. Most of the execs, including former VP and director of scientific development Robert Murphey, former VP-medical affairs Frederick Clark, and present board member William Zimmer have agreed to refund their awards.
You may also be interested in...
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?
Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.